Early access to drug discovery seeds through participation in the AMED New Modality Consortium

「In July, our admission as one of the member companies of the New Modality Consortium established by the Japan Agency for Medical Research and Development (AMED) was approved. This will enable us to gain efficient and early access to advanced drug discovery seeds held by universities and research institutions. By combining these with our antibody technologies, we expect to create new drug candidates and innovative drug discovery programs.」